logo
Plus   Neg
Share
Email

Waters Guides Q4, FY20 Adj. EPS Below Estimates - Quick Facts

While reporting financial results for the fourth quarter on Tuesday, specialty measurement company Waters Corp. (WAT) initiated its adjusted earnings and constant currency sales growth outlook for the full-year 2020 and for the first quarter of fiscal 2020.

For fiscal 2020, the company now projects adjusted earnings to be in a range of $9.15 to $9.40 per share on constant currency sales growth in a range of 1 to 3 percent. Currency translation currently is expected to decrease full-year sales growth by less than one percentage point.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $9.80 per share on sales growth of 3.50 percent to $2.49 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company expects adjusted earnings in a range of $1.55 to $1.65 per share on constant currency sales growth in the range of flat to 2 percent. Currency translation is currently expected to decrease quarterly sales growth by less than one percentage point.

The Street expects the company to report earnings of $1.75 per share on a sales growth of 3.0 percent to $529.07 million for the quarter.

The company noted that the potential impact from the coronavirus on its business cannot be reasonably estimated at this time, and as a result, is not reflected in the Company's first quarter and fiscal year 2020 guidance.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
RELATED NEWS
Follow RTT